Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aminolevulinic acid
Drug ID BADD_D00110
Description A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Indications and Usage Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
Marketing Status approved
ATC Code L01XD04
DrugBank ID DB00855
KEGG ID D07567
MeSH ID D000622
PubChem ID 137
TTD Drug ID D0Y7ZD
NDC Product Code 46016-5450
UNII 88755TAZ87
Synonyms Aminolevulinic Acid | Acid, Aminolevulinic | Delta-Aminolevulinic Acid | Acid, Delta-Aminolevulinic | Delta Aminolevulinic Acid | Levulan | 5-Aminolaevulinate | 5 Aminolaevulinate | 5-Aminolevulinate | 5 Aminolevulinate | Aminolevulinic Acid Hydrochloride | Acid Hydrochloride, Aminolevulinic | Hydrochloride, Aminolevulinic Acid
Chemical Information
Molecular Formula C5H9NO3
CAS Registry Number 106-60-5
SMILES C(CC(=O)O)C(=O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Amnesia19.20.01.001; 17.03.02.0010.000112%
Amylase increased13.05.01.009--
Anaemia01.03.02.001--
Aphasia19.21.01.001; 17.02.03.001--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.0010.004164%Not Available
Application site irritation12.07.01.003; 08.02.01.0030.000381%Not Available
Application site oedema12.07.01.020; 08.02.01.0200.000381%Not Available
Application site pain12.07.01.004; 08.02.01.0040.003481%Not Available
Application site pruritus12.07.01.005; 08.02.01.005; 23.03.12.0040.000571%Not Available
Application site reaction08.02.01.006; 12.07.01.0060.000571%Not Available
Application site warmth12.07.01.029; 08.02.01.0290.000381%Not Available
Aspartate aminotransferase increased13.03.04.011--
Basal cell carcinoma23.08.02.001; 16.03.02.0010.000224%Not Available
Blister23.03.01.001; 12.01.06.0020.000381%Not Available
Blood bilirubin increased13.03.04.018--
Body temperature increased13.15.01.001--Not Available
Burning sensation17.02.06.001; 08.01.09.0290.000246%Not Available
Chills08.01.09.001; 15.05.03.016--
Dermatitis23.03.04.002--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.0040.001142%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Drug ineffective08.06.01.0060.005003%Not Available
Dry skin23.03.03.001--
Dysaesthesia23.03.03.077; 17.02.06.003--
Embolism venous24.01.01.003--Not Available
Erythema23.03.06.0010.001007%Not Available
Eye disorder06.08.03.001--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene